PROBES FOR THE DIAGNOSIS OF INFECTIONS CAUSED BY STREPTOCOCCUS PYOGENES

Abstract: Probes obtained by extracting DNAs carried by Streptococcus pyogenes , completely digesting the extracted DNAs with a restriction enzyme HindIII, cloning the same into an appropriate vector and then screening probes containing the DNA fragments inherently carried by S. pyogenes , followed by the clarification of the base sequences of these probes.

Description: [Field of the Invention] The present invention relates to a probe which is useful for detecting and identifying Streptococcus pyogenes , the causative bacteria of infectious diseases such as pharyngitis, rheumatic fever, nephritis, erysipelas, scarlatina, sepsis and the like. [Back Ground Art] Generally, the diseases caused by infection of pathogenic microorganisms are called infectious diseases. In pathology, "infection" is defined as an invasion of pathogenic microorganisms (hereinafter referred to as "bacteria") and an establishment of footholds for the growth in the host organism by the pathogenic microorganisms. Thereafter, the outbreak of the disease states caused by proliferation of the pathogenic microorganisms in vivo depends upon the relationship between the resistance of the host and the virulence of the bacteria. Streptococcus is a genus of gram-positive facultative or obligate anaerobe, which exhibits the chain like arrangement. According to the characteristic appearances of hemolytic rings formed around the colonies grown on blood agar medium, the member of this genus is classified into three types: α, β, and γ. Moreover, the members of this genus are further classified into 20 groups from A to V (except I and J) in dependence upon their antigenicity of C-polysaccharide contained in the bacteria (Lancefield classification). Streptococcus pyogenes is a member of Streptococcus Group A under Lancefield classification, which shows β-type hemolysis (i.e., complete hemolysis), and is of clinical importance as causative bacteria of human pharyngitis, tonsillitis, scarlatina, erysipelas, puerperal fever, sepsis and the like. It is also known as the causative bacteria for the allergic diseases which are referred to as post-streptococcal diseases such as rheumatic fever or nephritis secondary to the initial infection. Furthermore, in recent years, the cases that exhibit severe septic shock with myositis (fulminant type Streptococcus Group A infection) due to Streptococcus pyogenes infection have been also reported. The patient suffering from pharyngitis upon Streptococcus pyogenes infection generally complains sore throat with significant erythrogenic pharynx and trachelopanus as well as pharyngeal pain, therefore, these clinical symptoms may suggest the infection of the bacteria and lead to the possible diagnosis. However, it is desirable to avoid the unnecessary administration of antibacterial agents while the optimal chemical therapy is extremely important to prevent the complications secondary to the infection, and in view of some cases not accompanied by evident clinical symptoms, development of the rapid and accurate bacteriological diagnosis has been desired. In addition, in the case of fulminant type Streptococcus Group A infection, more than 50% of the cases were reported to result in complications with severe necrotizing tasciitis, therefore it can be easily progressed to multiple organ failure and even to death. Streptococcus pyogenes is generally known to be highly sensitive to β -lactam agents such as ampicillin and cefaclor. However, approximately 30% of the bacterial strains are highly resistant to erythromycin, and the appearance of ofloxacin resistant strains has also been reported, therefore, the most attention has to be paid at administration with macrolide derivatives or new-quinolone derivatives. Consequently, it is essentially important to perform the accurate diagnosis at an early stage of infection and select the optimal antibacterial agents in the cases of the infectious diseases caused by Streptococcus pyogenes as described above. In general biological procedure, it is mandatory to : (1) analyze the clinical symptoms; (2) culture the specimen; and (3) isolate and identify Streptococcus pyogenes from the cultures, and then the therapeutic strategy is determined after these items are sufficiently examined. The method to identify Streptococcus pyogenes comprises direct smear culturing of the specimen on a blood agar plate which is supplemented with 5% sheep or horse defibrinated blood and monitoring the characteristic appearances of the hemolytic rings around the colonies grown on the plate. However, it is always accompanied by the difficulties in the identification of the causative bacteria. Actual identification of the causative bacteria is quite difficult because of a variety of shapes of the colonies which are formed dependent upon the culture conditions, thus, the identification is avoided. Also, the bacteria from the specimen have to be proliferated for a long time in the appropriate medium to the number large enough for applying the drug sensitivity test, and then at least 3 to 4 days of incubation period is required to attain the result of the test. Thus the rapid diagnosis can not be achieved in accordance with the above process. Additionally, in cases of the diagnosis of the patients who had already been treated with a large dose of antibiotics when the possible infection was suspected, the growth and proliferation of the bacteria may be prevented even if the bacteria are present in the specimen. Accordingly, the feasibility of successful culture of the bacteria from these specimen may become extremely low. Furthermore, alternative subroutine methods developed heretofore may include: an instrumental analysis method of constituents of bacteria and metabolic products from bacteria (See Yoshimi Benno, "Quick identification of bacteria with gas chromatography", Rinsho Kensa, Vol. 29, No.12 pp.1618-1623, November 1985, Igaku Shoin.); a method utilizing a specific antibody (See Japanese Patent Provisional Publication No.60-224068.); and a hybridization method utilizing a specificity of DNA (Japanese Patent Provisional Publication No. 61-502376), however, any of which requires the steps for isolation of the bacteria, as well as the steps for culturing and growing the bacteria. On the other hand, an established method based on the function of the phagocyte in the infectious diseases has been proposed, wherein a stained smear of buffy coat in which leukocytes constituents in the blood sample are concentrated is examined under an optical microscope. Generally speaking, the detection rate of bacteria in buffy coat specimens from adult bacteremia patients is 30% at most, which is similar to that in blood specimens from ear lobes, however, it was reported that in case that the patients are newborn children, the bacteria could be detected in seven cases in ten (70%). Therefore, information concerning the presence of bacteria in peripheral blood obtained by a microscopic prospection on a smear can provide an important guiding principle for the therapeutic treatment. The above mentioned conventional methods necessitate the pretreatment which requires at least three to four days in total, containing one to two days for the selective isolation of bacteria from a specimen, one day for proliferating cultivation, and one or more days for operation of fixation, and the culture thereof should be continued in practice until the bacteria grow enough, therefore, the pretreatment may require one week or more days. In addition, any bacteria other than the causative bacteria may be contaminated during the culture step in some cases, and such contaminants may not be distinguished from the causative bacteria. More importantly, as mentioned above, because many of the causative bacteria in the specimen to be proliferated and detected have been uptaked into phagocytes, and are already dead or in a bacteriostatic state due to the antibiotics administered, the number of bacteria that can be grown may be small even under appropriate conditions for the culture of the causative bacteria, thereby, the actual detection rate of bacteria is as low as about 10% when the clinical culture specimen is employed. In the other words, for the present, 90% of the examined blood from the patient clinically suspected as suffering from the infection of Streptococcus pyogenes could not be identified for the presence of the bacteria after all, even though the culture is continued for further one or more days. Although the determination of the causative bacteria and selection of the antibiotics suitable for killing the bacteria as quick as possible have been eminently desired, in light of the present situation as above, the presently employed practice depends upon a therapeutic treatment which is initiated when the infection of Streptococcus pyogenes is clinically suspected without awaiting the results of the detection of the causative bacteria. That is to say, a trial and error method has been practiced wherein an antibiotic having the effectiveness for the widest range of spectra against many kinds of bacteria is administered first, and next, if the antibiotic is shown to be not effective after one or two days, another antibiotic will be tested. Recently, rapid methods for the diagnosis of the infections of Streptococcus pyogenes to immunologically detect the bacteria using the procedures such as latex agglutination assay, co-agglutination assay, enzyme immunoassay, gold particle assay and liposome immunoassay have been developed. All of these methods are carried out by extracting C-polysaccharide on the surfaces of the bacterial bodies of Streptococcus pyogenes with nitrous acid or enzymes, and detecting the presence of the bacteria using the polysaccharide as an antigen. However, the above immunological methods are problematic because the results thereof are often inconsistent with the results obtained by the culture method (namely, indicating false positive or false negative results), and because the manipulation for carrying out the methods are complicated. Further, species specificity of this immunological method is not satisfactory due to the properties of this diagnosis method in which antigen-antibody reactions are utilized, namely, detection of the bacteria except for Streptococcus pyogenes, which carry Group A antigen (e.g., Streptococcus anginosus , and the like) may be obliged. Meanwhile, a diagnostic guideline for the clinical diagnosis of the infections caused by fulminant Group A Streptococcus has been also proposed (JAMA, Vol.269, 390-391, 1993), however, it is not applicable to the early diagnosis. Although the infectious diseases caused by Streptococcus pyogenes are diseases of which rapid and accurate diagnosis has been required, the conventional diagnosis method could not have complied with such demands. [Disclosure of the Invention] The present invention was accomplished in view of the above-described problems in this art, and is directed to probes for diagnosis of infectious diseases, which comprise a DNA fragment obtainable by treating DNA from the causative bacteria Streptococcus pyogenes with restriction enzyme HindIII, wherein said probe consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1, 2, 3, 4, 5 and 6, and wherein said probe specifically hybridizes to the DNA from Streptococcus pyogenes . Accordingly, the bacterial DNA still included in the bacteria but in the process of breakdown through phagocytosis by phagocytes can be significantly detected based on its specificity using hybridization method. Therefore, rapid and accurate detection of the causative bacteria of infectious diseases can be achieved without culturing and proliferation of the bacteria. Moreover, identification of the causative bacteria can be accomplished through DNA amplification using PCR method without the hybridization process when a primer is designed with reference to the nucleotide sequence information of the probes of the present invention. In addition, the probe used for the hybridization may be labeled with non-radioactive agent. If biotinylated probe is used for example, the detection can be carried out in a general examination laboratory not having a facility for radioisotope handling. Thus, operation for the detection can be practiced in a rapid and simple way. [Brief Description of Drawings] Figure 1 (a) is a drawing which shows the positions of the originated bacterial strains of the DNAs on each of the filters of dot blot hybridization, and Figure 1 (b) shows the results obtained by color development after the hybridization process using each probe. [Best Mode for Carrying out the Invention] In order to explain the present invention in more detail, non-limiting Examples with respect to the probes which are derived from Streptococcus pyogenes , causative bacteria of infectious diseases are shown below. Example 1: DNA probe derived from Streptococcus pyogenes (1) Preparation of DNA probes derived from the bacteria Streptococcus pyogenes Clinical isolate of Streptococcus pyogenes was cultured overnight in BHI (Brain Heart Infusion) medium, then the cultured cells were harvested, and genomic DNA was extracted therefrom in accordance with Saito-Miura modified method ("Preparation of transforming deoxyribonucleic acid by phenol treatment", Biochem. Biophys. Acta vol. 72 , pp.619-629 (1963)) in which cell lysis step was carried out by adding N-Acetylmuramidase SG to the lysis buffer. The extracted DNA was completely digested with restriction enzyme Hind III, then random cloned into vector pGEM-3Z. Six probes specific to Streptococcus pyogenes , that is to say, the probes comprising DNA fragments which showed specific reactivities toward DNA included in natural Streptococcus pyogenes , were selected from thus obtained clones. Thereafter, the selected probes were named: probe SP-6-28, probe SP-7-44, probe SP-14-1, probe SP-26-36, probe SP-26-46, and probe SP-55-3. (2) Studies of species specificity of the DNA probes derived from Streptococcus pyogenes Interactions between each probes and DNAs from several kinds of causative bacterial strains of infections were studied as follows. First, the clinical isolates and deposited bacterial strains as listed in Table 1 below were prepared. In order to obtain the sources of Human genomic DNA in Table 1 and a control sample, leucocytes which were collected from four healthy adult men, and Escherichia coli K-12, JM109 transformant containing plasmid pGEM-3Z were respectively prepared. Bacteria No. Abbrev. Name Origin 1 SP Streptococcus pyogenes Clinical Isolate 2 SAG Streptococcus agalactiae Clinical Isolate 3 SPN Streptococcus pneumoniae NYSDH DP-2 4 SA Staphylococcus aureus ATCC 25923 5 SE Streptococcus epidermidis ATCC 12228 6 EC Escherichia coli ATCC 25922 7 KP Klebsiella pneumoniae Clinical isolate 8 EBC Enterobacter cloacae Clinical Isolate 9 EF Enterococcus faecalis Clinical Isolate 10 PA Pseudomonas aeruginosa ATCC 27583 11 HIN Haemophills influenzae Clinical Isolate 12 HUM U937 Human Genomic DNA [ABBREVIATION] NYSDH : New York State Department of Health (Albany,New York,USA) Thereafter, the DNAs included in each of the clinical isolates were extracted according to the method described in Example 1(1), then the aliquot of the extracted DNA (e.g., 10-100 ng) was spotted onto a nylon filter. After denaturation with alkali, the filter was subjected to dot blot hybridization. The human genomic DNA sample was prepared from the leukocyte obtained as mentioned previously using Saito-Miura modified method (supra). A control sample was prepared from Escherichia coli K-12, JM109 transformant containing plasmid pGEM-3Z using the method for preparation of plasmid DNA described in the following Example 2(1). Hybridization was then carried out overnight using a Digoxigenin-11-dUTP (BRL) labeled DNA probe which was derived from the Streptococcus pyogenes under a hybridization condition of 45% formamide, 5 x SSC, at 42°C according to Manual by Maniatis (T. Maniatis,et al., "Molecular Cloning (A Laboratory Manual Second Edition)"., Cold Spring Harbour Laboratory (1989)). After overnight hybridization was completed, the samples were washed two times with 0.1 x SSC, 0.1% SDS at 55°C for 20 min. according to the manual, followed by color development and detection using Anti-Dig-ALP comjugates (BRL), thus results of hybridization were revealed. These results are shown in Fig.1, wherein Fig 1(a) illustrates the positions of the originated bacterial strains of the DNAs on each of the filters of dot blot hybridization, and Figure 1 (b) illustrates the results obtained by color development after the hybridization process using each of the above mentioned probes SP-6-28, SP-7-44, SP-14-1, SP-26-36, SP-26-46 and SP-55-3. The experimental results with respect to the reactivities between each probes and DNAs from each of the clinical bacteria strains are shown in Table 2 below. Bacteria No. Abbrev. Name Probe (Denotation: SP-) 6-28 7-44 14-1 26-36 26-46 55-3 1 SP Streptococcus pyogenes + + + + + + 2 SAG Streptococcus agalactiae - - - - - - 3 SPN Streptococcus pneumoniae - - - - - - 4 SA Staphylococcus aureus - - - - - - 5 SE Staphylococcus epidermidis - - - - - - 6 EC Escherichia coli - - - - - - 7 KP Klebsiella pneumoniae - - - - - - 8 EBC Enterobacter cloacae - - - - - - 9 EF Enterococcus faecalis - - - - - - 10 PA Pseudomonas aeruginosa - - - - - - 11 HIN Haemophills influenzae - - - - - - 12 HUM U937 Human Genomic DNA - - - - - - [REMARKS] +: hybridization signal detected -: hybridization signal not detected As is evident from the Tables 1 and 2 above, all of the present probes showed reactivities only to the DNA derived from Streptococcus pyogenes , while no reactivity (i.e., hybrid formation) was observed toward the DNAs from the every other bacterial species in the genus Streptococcus, as well as the DNAs from the bacterial species other than genus Streptococcus . Thus, the specificity of the probes was demonstrated. Example 2: Analysis of the Base Sequence Each of the base sequences of the DNA probes (six probes in total) of which species specificity was demonstrated in Example 1 as above was determined according to the following procedure. (1) Preparation of Plasmid DNA Eseherichia coli K-12, JM109 transformant, wherein the sub-cloned insert fragment (to be sequenced) is contained in pGEM-3Z (Promega), was inoculated into 5ml of Luria-Bactani Medium (bacto-tryptone, 10g/1L; bacto-yeast extract, 5g/1L; NaCl, 10g/1L; adjusted pH to 7.0 with 5N NaOH) and cultured overnight. The culture liquid mixture was centrifuged (5,000rpm, 5min.) to collect the bacteria. One hundred µl of a solution of 50mM glucose/50mM Tris-HCl (pH8.0)/10mM EDTA containing 2.5mg/ml of lysozyme (Sigma) was added to the precipitate, and left at room temperature for 5 minutes. To the suspension, 0.2M NaOH solution containing 1% of sodium dodecyl sulfate (Sigma) was added and mixed. One hundred and fifty µl of 5M potassium acetate aqueous solution (pH 4.8) was further added thereto and mixed, then cooled on ice for 15 minutes. The supernatant collected by centrifugation (15,000rpm, 15min.) of the mixture was treated with phenol/CHCl 3 , and ethanol of two times by volume was added thereto, then the precipitate was again obtained by centrifugation (12,000rpm, 5min.). This precipitate was dissolved in 100µl of a solution of 10mM Tris-HCl (pH7.5)/0.1mM EDTA, followed by addition of 10mg/ml RNase A (Sigma) solution, then the mixture was left at room temperature for 15 minutes. Three hundred µl of 0.1M sodium acetate aqueous solution (pH 4.8) was added to this mixture and treated with phenol/CHCl 3 , then the precipitate was obtained therefrom by adding ethanol to the supernatant. This precipitate was dried and dissolved in 10µl of distilled water to give a DNA sample. (2) Pretreatment for Sequencing Pretreatment for sequencing was performed with AutoRead™ Sequencing Kit (Pharmacia). Concentration of DNA to be employed as a template was adjusted to 5-10µg in 32µl of a solution. Thirty two µl of the template DNA solution was transferred to a mini-tube (1.5ml, Eppendolf), and added thereto 8µl of 2M NaOH aqueous solution, then mixed gently. After instant centrifugation, it was left at room temperature for 10 minutes. Seven µl of 3M sodium acetate (pH 4.8) and 4µl of distilled water were added, followed by 120µl of ethanol, and after mixing, the mixture was left for 15 minutes on ethanol/dry ice. DNA which was precipitated by centrifugation for 15 minutes was collected, and the supernatant was removed carefully. The precipitate thus obtained was washed with 70% ethanol and centrifuged for 10 minutes. Then, after the supernatant was carefully removed again, the precipitate was dried under the reduced pressure. The precipitate was dissolved in 10 µl of distilled water, then 2µl of fluorescent primer (0.42 A 260 unit/ml, 4-6 pmol (Fluorescent Primer; Universal Primer: 5'-Fluorescein-d[CGACGTTGTAAAACGACGGCCAGT (SEQ ID NO: 7)]-3' (1.6pmol/µl, 0.42 A 260 unit/ml); Reverse Primer: 5'-Fluoresceind[CAGGAAACAGCTATGAC (SEQ ID NO: 8)]-3' (2.1 pmol/µl, 0.42 A 260 unit/ml), and 2µl of annealing buffer was added thereto, and mixed gently. After instant centrifugation, the mixture was heat-treated at 65°C for 5 minutes and rapidly transferred to a circumstance of 37°C and kept the temperature for 10 minutes. After keeping the temperature, it was left at room temperature for more than 10 minutes, and centrifuged instantly. Then, the sample was prepared by adding thereto 1µl of elongation buffer and 3µl of dimethyl sulfoxide. Four mini-tubes have been identified with one of the marks of "A", "C", "G" and "T", and, according to the respective mark, 2.5 µl of A Mix (dissolved ddATP with dATP, dCTP, c 7 dGTP and dTTP), C Mix (dissolved ddCTP with dATP, dCTP, c 7 dGTP and dTTP), G Mix (dissolved ddGTP with dATP, dCTP, c 7 dGTP and dTTP), or T Mix (dissolved ddTTP with dATP, dCTP, c 7 dGTP and dTTP) was poured into each identified tube. Each solution was preserved on ice until use, and was incubated at 37 °C for one minute or more before use. Two µl of diluted T7 DNA polymerase (Pharmacia; 6-8 units/2µl) was added to the DNA sample, and completely mixed by pipetting or mixing it gently. Immediately after completion of the mixing, the mixed solution was distributed to 4.5µl of the four types of the solutions respectively which had been incubated at the same temperature. Fresh tips were used for each distribution. The solutions were kept for 5 minutes at 37°C, then 5µl of termination solution was added to each reaction mixture. Fresh tips were also used for this step. Immediately after incubating the solution for 2-3 minutes at 90 °C, it was cooled on ice. Four to six µl of the solution per lane was applied for the electrophoresis. (3) Sequencing on Base Sequences Sequencing on the base sequences of the probes disclosed in Examples 1 and 2, having the specificity toward DNA from Streptococcus pyogenes was performed using A.L.F. DNA Sequencer System (Pharmacia) under a condition of the electrophoresis process of 45 °C for 6 hours. Primers were serially designed based on the sequences elucidated from each of the upstream and downstream sequences, and the above described procedures were repeated. Consequently, all of the entire base sequences of the probe SP-6-28 (SEQ ID NO: 1), probe SP-7-44 (SEQ ID NO: 2), probe SP-14-1 (SEQ ID NO: 3), probe SP-26-36 (SEQ ID NO: 4), probe SP-26-46 (SEQ ID NO: 5) and probe SP-55-3 (SEQ ID NO: 6) were elucidated. [Industrial Applicability] Using the probes according to the present invention, the causative bacteria which were incorporated into the phagocytes can be rapidly and accurately identified directly without proliferation of the bacteria by for example, a hybridization method. In other words, the diagnosis wherein the probes of the present invention are used enables the identification of the causative bacteria with single specimen, further, the necessary time for diagnosis can be diminished to approximately 1 to 2 days, while the conventional method with low detection rate requires 3-4 days, and the resulting detection rate is remarkably improved. Therefore, the present application discloses guiding principles for the therapeutic treatment for the infectious diseases caused by Streptococcus pyogenes , in addition, the effective treatment in an early stage of the infection can be adopted to the patients, which may lead to a reduction of the mortality. Additionally, in accordance with the present invention wherein the base sequences of the probes which specifically react with the DNA derived from Streptococcus pyogenes among other several causative bacteria of the infectious diseases were elucidated, artificial preparation of these probes has become feasible. Moreover, a part of the information of the base sequences provided herein may be utilized to produce primers, which are useful for rapid diagnosis through amplification of DNA of causative bacteria contained in the clinical specimen by a PCR method. Furthermore, the rapid identification of the causative bacteria may be carried out by comparing the base sequences of the genomic DNA from the clinical specimen with the base sequences provided by the present invention. As stated above, the present invention provides the desired probe for the diagnosis of the infections, besides, outstanding utilities as guiding principles for the manufacture of the primers for PCR as well as standard sequences which are suitable for the comparison of genomic DNA contained in the clinical specimen can be expected. Moreover, the present invention may exert beneficial effects by providing valuable clues for preparation and development of the novel probes which specifically react with the DNA from the causative bacteria of the infectious diseases. Further, the base sequence disclosed in the present application was obtained by random-cloning of the genomic DNA from the clinical isolates, therefore, the utilities of the base sequences of the present invention should be encompassed to the complementary strand thereof. Additionally, it may be presumed that DNA obtained from the wild strains might contain the mutated portion. However, as apparent from the disclosure of the Examples above, such mutated DNA portion would not affect the utilities which should be derived from the present invention, comprising the specificity of the probe of the present invention in the hybridization procedure for the diagnosis of the infections, and usages of the information on the base sequences disclosed in the present application for designing the primer to be employed for the PCR techniques with the aim of a rapid diagnosis of the infections. SEQUENCE LISTING (1) Applicant: Fuso Pharmaceutical Industries, Ltd. (2) Title: Probe for Diagnosis of Infectious Disease Caused by Streptococcus pyogenes (3) Docket Number: 98P055WO (4) Description of the Priority Filing: Country: Japan Application Number: 1997-71077 (5) Priority Date: March 25, 1997 (6) Number of Sequences: 8 INFORMATION FOR SEQ ID NO: 1 LENGTH: 3549 base pairs TYPE: nucleic acid STRANDENESS: double TOPOLOGY: linear MOLECULAR TYPE: Genomic DNA ORIGINAL SOURCE: ORGANISM: Streptococcus pyogenes STRAIN: Clinical Isolate SP-6-28 SEQUENCE DESCRIPTION: SEQ ID NO: 1 : INFORMATION FOR SEQ ID NO: 2 LENGTH: 3200 base pairs TYPE: nucleic acid STRANDENESS: double TOPOLOGY: linear MOLECULAR TYPE: Genomic DNA ORIGINAL SOURCE: ORGANISM: Streptococcus pyogenes STRAIN: Clinical Isolate SP-7-44 SEQUENCE DESCRIPTION: SEQ ID NO: 2 : INFORMATION FOR SEQ ID NO: 3 LENGTH: 5014 base pairs TYPE: nucleic acid STRANDENESS: double TOPOLOGY: linear MOLECULAR TYPE: Genomic DNA ORIGINAL SOURCE: ORGANISM: Streptococcus pyogenes STRAIN: Clinical Isolate SP-14-1 SEQUENCE DESCRIPTION: SEQ ID NO: 3 : INFORMATION FOR SEQ ID NO: 4 LENGTH: 7143 base pairs TYPE: nucleic acid STRANDENESS: double TOPOLOGY: linear MOLECULAR TYPE: Genomic DNA ORIGINAL SOURCE: ORGANISM: Streptococcus pyogenes STRAIN: Clinical Isolate SP-28-36 SEQUENCE DESCRIPTION: SEQ ID NO: 4 : INFORMATION FOR SEQ ID NO: 5 LENGTH: 6688 base pairs TYPE: nucleic acid STRANDENESS: double TOPOLOGY: linear MOLECULAR TYPE: Genomic DNA ORIGINAL SOURCE: ORGANISM: Streptococcus pyogenes STRAIN: Clinical Isolate SP-26-46 SEQUENCE DESCRIPTION: SEQ ID NO: 5 : INFORMATION FOR SEQ ID NO: 6 LENGTH: 4973 base pairs TYPE: nucleic acid STRANDENESS: double TOPOLOGY: linear MOLECULAR TYPE: Genomic DNA ORIGINAL SOURCE: ORGANISM: Streptococcus pyogenes STRAIN: Clinical Isolate SP-55-9 SEQUENCE DESCRIPTION: SEQ ID NO: 6 : INFORMATION FOR SEQ ID NO: 7 LENGTH: 24 base pairs TYPE: nucleic acid STRANDENESS: single TOPOLOGY: linear MOLECULAR TYPE: Other Nucleic Acid (Synthetic DNA) SEQUENCE DESCRIPTION: SEQ ID NO: 7 : INFORMATION FOR SEQ ID NO: 8 LENGTH: 17 base pairs TYPE: nucleic acid STRANDENESS: single TOPOLOGY: linear MOLECULAR TYPE: Other Nucleic Acid (Synthetic DNA) SEQUENCE DESCRIPTION: SEQ ID NO: 8 :

Claims: A probe for diagnosis of infectious diseases, which comprises a DNA fragment obtainable by treating DNA from the causative bacteria Streptococcus pyogenes with restriction enzyme HindIII, wherein said probe consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1, 2, 3, 4, 5 and 6, and wherein said probe specifically hybridizes to the DNA from Streptococcus pyogenes . Use of a probe as claimed in claim 1 for the in vitro diagnosis of infections caused by Streptococcus pyogenes .

Inventors: ABE KANAKO, KESHI HIROYUKI, MATSUHISA AKIO, UEYAMA HIROSHI, ABE, KANAKO, KESHI, HIROYUKI, MATSUHISA, AKIO, UEYAMA, HIROSHI
Applicants: FUSO PHARMACEUTICAL IND, FUSO PHARMACEUTICAL INDUSTRIES LTD.
Application year: 1998
Main classification: C12N15
IPC codes: C07H21, C12R1, C12Q1, C07K14, C12N15